Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi Snaps Up Qpex to Boost Antimicrobial Pipeline
June 27, 2023
- Zenyaku Kogyo Bags Japan Rights to Singapore Firm’s Eczema Med
June 26, 2023
- Veritas, Takeda Link Up for mRNA-Targeted Drug Discovery against Genetic Disorders
June 26, 2023
- Japan Pharma Market Projected to Grow 0.5-1.5% through FY2027: IQVIA
June 26, 2023
- Nobelpharma Grants Authorized Generic Rights to Japanese Firm
June 26, 2023
- Shionogi CEO Hauls In 292 Million Yen after Record Year
June 26, 2023
- Kris Sisneros Takes Helm at LEO Pharma Japan
June 23, 2023
- Gilead Completes Marketing Authorization Transfer for Yescarta in Japan
June 23, 2023
- Astellas Chairman Snags 452 Million Yen in FY2022: Securities Report
June 23, 2023
- Combined Sales of 26 Japan Drug Makers Up 13.6% in FY2022 on Global Growth, COVID Demand
June 22, 2023
- Nippon Shinyaku Files Jazz’s High-Risk AML Drug in Japan
June 22, 2023
- 4 Eisai Execs Earn 100 Million Yen-Plus Pay, CEO Takes Home 157 Million Yen
June 22, 2023
- Global Pharma Market Grows 8.3% in 2022, Humira Top-Seller Drug: IQVIA
June 21, 2023
- ASKA Seeks Pediatric Indication for Rifxima in Japan
June 21, 2023
- Wegovy Rollout Being Delayed due to Unprecedented Demand: Novo Japan Chief
June 21, 2023
- Daiichi Sankyo Chair Snares 402 Million Yen in FY2022: Securities Report
June 20, 2023
- Entyvio SC Now Available in Japan: Takeda
June 20, 2023
- Mitsubishi Tanabe VC Firm Certified for AMED Startup Project
June 19, 2023
- Hutchmed’s Colorectal Cancer Med Accepted for European Review: Takeda
June 19, 2023
- As Wholesalers Try to Negotiate Higher Prices, Hospitals Face Tougher Haggling This Year
June 16, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…